Vantictumab

From Wikipedia, the free encyclopedia
Vantictumab
Monoclonal antibody
Type?
SourceHuman
TargetFrizzled receptor
Clinical data
Routes of
administration
IV
ATC code
  • none
Identifiers
CAS Number
  • 1345009-45-1
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC6322H9722N1674O1988S46
Molar mass142461.81 g·mol−1

Vantictumab /vænˈtɪktʊmæb/ is a human IgG2 monoclonal antibody designed for the treatment of cancer.[1]

This drug was developed by OncoMed Pharmaceuticals Inc. in partnership with Bayer.[2] OncoMed was awarded a patent in 2016, which is set to expire in 2029.[3] In April 2017, Bayer terminated its option to license vantictumab.[4]

It inhibits wnt signalling by targeting the frizzled receptors on cancer cells.[5]

Phase I trials have been completed for pancreatic cancer, non-small cell lung cancer, and breast cancer. In 2016 results were reported from a phase 1b clinical trial for triple-negative breast cancer.[5]

References[]

  1. ^ "Statement on a nonproprietary name adopted by the USAN Council" (PDF). AMA. 28 Nov 2012. N12/155.{{cite web}}: CS1 maint: url-status (link)(registration required)
  2. ^ "OncoMed Pre-Announces 2014 Year-End Cash Balance and Provides 2015 Guidance". 12 January 2015.
  3. ^ http://investor.shareholder.com/oncomed/secfiling.cfm?filingID=1564590-16-14426&CIK=1302573
  4. ^ "BRIEF-Oncomed Pharmaceuticals announces Bayer terminates its option to license vantictumab or ipafricept". Reuters. 10 April 2017.
  5. ^ a b Finally, targeted therapies for triple-negative breast cancer. June 2016
Retrieved from ""